ARWR - Arrowhead Pharmaceuticals GAAP EPS of $0.41 beats by $0.12 revenue of $151.8M beats by $29.65M May, 10 2022 04:01 PM Arrowhead Pharmaceuticals Inc. Arrowhead Pharmaceuticals press release (NASDAQ:ARWR): Q2 GAAP EPS of $0.41 beats by $0.12. Revenue of $151.8M (+362.7% Y/Y) beats by $29.65M. For further details see: Arrowhead Pharmaceuticals GAAP EPS of $0.41 beats by $0.12, revenue of $151.8M beats by $29.65M